The calcineurin signaling pathway is a critical mediator of pressure overload-induced cardiac hypertrophy, representing a potential therapeutic target.
Calcineurin inhibition merits testing as anti-hypertrophic therapy; animal data leave human translation unresolved.
The present results suggest that the calcineurin signaling pathway plays a pivotal role in load-induced cardiac hypertrophy and may pave the way for a novel pharmacological approach to prevent cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Shimoyama et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: